Gastroenterology

More European Data Back the Use of Biosimilar CT-P13 in IBD

July 18th 2019

By Kelly Davio

Article

The retrospective, observational, multicenter study included 141 patients, 96 with ulcerative colitis and 45 with Crohn disease, at 14 centers in Italy.

In IBD, Switching to Biosimilar Infliximab Remains Safe and Effective at 2 Years, Study Finds

July 11th 2019

By Kelly Davio

Article

The study, conducted at a hospital in Spain from 2015 to 2017, included all 100 patients who were switched to the biosimilar from the reference infliximab when the hospital transitioned to using the lower-cost product.

In Switching to Biosimilar Infliximab in IBD, Rapid Infusion Protocols Are Safe

July 2nd 2019

By Kelly Davio

Article

As more centers begin to switch patients from reference infliximab to biosimilar options, patients who have benefitted from rapid infusions of the reference product may want to continue to receive time-saving infusions that reduce the burden of lengthy visits to infusion centers.

More Data Underscore the Importance of Educating Patients as Part of a Biosimilar Switch in IBD

July 1st 2019

By Kelly Davio

Article

In a study conducted from 2017 to 2018 among all of the infliximab-treated patients with inflammatory bowel disease (IBD) in a single center, patients who were in clinical remission were invited to complete a questionnaire to assess their biosimilar knowledge and acceptance of a switch.

Infliximab Did Not Result in Lower Rate of Hospitalizations, Surgeries in Canadian Study

June 13th 2019

By Allison Inserro

Article

The introduction of infliximab for the treatment of inflammatory bowel diseases (IBD) did not result in lower population rates of hospitalizations or intestinal surgeries among patients living with IBD in Ontario, Canada, according to a study published Thursday.

Working Group Releases Recommendations for Improving Treatment of IBD in Asia Through Biologics, Biosimilars

June 12th 2019

By Allison Inserro

Article

A new consensus paper from the Asia-Pacific Working Group on inflammatory bowel disease (IBD) released a set of best practices for improving IBD care with biologics and biosimilars.

Real-World Data Suggest CT-P13 Carries Lower Risk of Infection Than Remicade

May 29th 2019

By Kelly Davio

Article

Infliximab and its biosimilars are often used as a treatment for ulcerative colitis (UC), and recent years have seen the collection of real-world data on the use of biosimilar CT-P13 (Inflectra, Remsima) that confirm the product’s equivalent efficacy to that of the reference, Remicade. One newly published study, which assessed patient data from a French nationwide health administrative database, found that not only is biosimilar CT-P13 as effective as the reference product in treating UC, it may also have a lower risk of serious infections.

In Pediatric Patients With IBD, Switching to CT-P13 Does Not Affect PK, Immunogenicity, or Efficacy

May 27th 2019

By Kelly Davio

Article

All children with inflammatory bowel disease (IBD) who were receiving maintenance infliximab at a single center between 2017 and 2018 were included in the study.

In CD, Subcutaneous CT-P13 Has Similar Efficacy and Safety to IV Formulation at 1 Year

May 22nd 2019

By Kelly Davio

Article

During Digestive Disease Week 2019, held May 18-21 in San Diego, California, researchers presented the 1-year results of a phase 1 trial of subcutaneous CT-P13 versus the intravenous formulation of the biosimilar in patients with Crohn disease (CD).

Biologics in IBD Linked With Lower Surgery Costs, Corticosteroid Use, and Opioid Use

May 19th 2019

By Kelly Davio

Article

Research presented at this week’s ISPOR 2019 meeting sheds important light on the impact of biologics on the use of other healthcare resources.